Portage Biotech (PRTG) Competitors $7.85 -0.18 (-2.24%) Closing price 03:59 PM EasternExtended Trading$7.55 -0.30 (-3.82%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTG vs. AKTX, CLSD, MURA, JATT, SNYR, BTAI, MAAQ, DYAI, KZR, and MIRAShould you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Akari Therapeutics (AKTX), Clearside Biomedical (CLSD), Mural Oncology (MURA), JATT Acquisition (JATT), Synergy CHC (SNYR), BioXcel Therapeutics (BTAI), Mana Capital Acquisition (MAAQ), Dyadic International (DYAI), Kezar Life Sciences (KZR), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Portage Biotech vs. Its Competitors Akari Therapeutics Clearside Biomedical Mural Oncology JATT Acquisition Synergy CHC BioXcel Therapeutics Mana Capital Acquisition Dyadic International Kezar Life Sciences MIRA Pharmaceuticals Portage Biotech (NASDAQ:PRTG) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation. Do insiders and institutionals believe in PRTG or AKTX? 13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 42.1% of Portage Biotech shares are held by company insiders. Comparatively, 38.1% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer PRTG or AKTX? Akari Therapeutics has a consensus price target of $5.00, indicating a potential upside of 481.40%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Portage Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Portage Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Akari Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PRTG or AKTX? In the previous week, Portage Biotech and Portage Biotech both had 1 articles in the media. Portage Biotech's average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score. Company Overall Sentiment Portage Biotech Neutral Akari Therapeutics Neutral Is PRTG or AKTX more profitable? Portage Biotech's return on equity of 0.00% beat Akari Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Portage BiotechN/A N/A N/A Akari Therapeutics N/A -78.03%-31.62% Which has more risk & volatility, PRTG or AKTX? Portage Biotech has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Which has better earnings and valuation, PRTG or AKTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPortage BiotechN/AN/A-$6.77M-$41.65-0.19Akari TherapeuticsN/AN/A-$19.79MN/AN/A SummaryPortage Biotech beats Akari Therapeutics on 6 of the 9 factors compared between the two stocks. Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTG vs. The Competition Export to ExcelMetricPortage BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.24M$3.08B$5.73B$9.76BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-0.1920.7830.3826.03Price / SalesN/A348.83428.56103.94Price / CashN/A43.2325.7828.79Price / Book-9.949.809.706.08Net Income-$6.77M-$54.08M$3.27B$265.64M7 Day Performance-1.88%4.92%3.95%3.11%1 Month Performance37.00%3.64%3.81%0.39%1 Year Performance22.27%8.20%31.26%18.52% Portage Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTGPortage Biotech0.6645 of 5 stars$7.85-2.2%N/A+33.8%$8.24MN/A-0.196AKTXAkari Therapeutics2.3041 of 5 stars$0.98-1.9%$5.00+409.7%-77.0%$31.57MN/A0.009CLSDClearside Biomedical1.8324 of 5 stars$0.40-5.8%$4.20+947.4%-60.5%$31.48M$4.17M-1.0830News CoverageMURAMural Oncology2.9165 of 5 stars$1.78-2.5%$12.00+576.1%-40.5%$30.75MN/A-0.21119JATTJATT AcquisitionN/A$1.74+4.8%N/A-43.7%$30.02MN/A0.003High Trading VolumeSNYRSynergy CHC4.3347 of 5 stars$3.24-6.9%$10.00+208.6%+2,820.0%$29.79M$33.70M8.5340News CoverageGap DownBTAIBioXcel Therapeutics4.5487 of 5 stars$4.90-13.7%$39.75+711.9%-52.5%$29.72M$2.27M-0.3990Gap DownMAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+771.9%$29.49MN/A0.001DYAIDyadic International2.7336 of 5 stars$0.80+0.7%$6.00+649.1%-40.0%$28.95M$3.49M-4.217KZRKezar Life Sciences3.5662 of 5 stars$3.90+1.0%$9.00+130.8%-36.4%$28.55M$7M-0.4060MIRAMIRA Pharmaceuticals2.9892 of 5 stars$1.42-4.4%$17.00+1,101.4%-23.2%$27.27MN/A-2.922 Related Companies and Tools Related Companies Akari Therapeutics Alternatives Clearside Biomedical Alternatives Mural Oncology Alternatives JATT Acquisition Alternatives Synergy CHC Alternatives BioXcel Therapeutics Alternatives Mana Capital Acquisition Alternatives Dyadic International Alternatives Kezar Life Sciences Alternatives MIRA Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTG) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access